1. What Is the Stereotactic Radiosurgery Market?
The Stereotactic Radiosurgery Market covers the specialised radiotherapy technique that delivers the precisely targeted high-dose radiation in a single fraction or up to 5 fractions to the intracranial targets. The targets include brain metastases, acoustic neuromas, meningiomas, arteriovenous malformations, and functional targets for the pain and movement disorder management. The technique uses the precise patient immobilisation and the stereotactic coordinate system that enables the radiation delivery with submillimetre accuracy to the treatment volume while sparing the adjacent brain. SRS systems include the cobalt-60 multisource system that uses the 192 cobalt-60 sources focused on the stereotactic target through the rigid head frame that provides the mechanical precision. The linear accelerator-based SRS uses the VMAT volumetric modulated arc therapy and the stereotactic cone collimation that modern linac systems deliver with the couch and gantry-based precision positioning. The robotic linac system uses the robotic arm to deliver the radiation from multiple non-coplanar angles without the rigid frame using the real-time image guidance. The SRS market is growing with the increasing use of the brain metastasis SRS as the alternative to the whole-brain radiation. The SRS avoids the cognitive decline that whole-brain RT causes in the cancer patient with the adequate performance status and the oligometastatic brain disease. The SRS can address the oligometastatic brain disease with 1 to 5 lesion-specific treatments that preserve the neurocognitive function.
2. Stereotactic Radiosurgery Market Size & Forecast
3. Emerging Technologies
- Brain metastasis SRS versus whole-brain radiotherapy randomised trials and the population-based data demonstrated the superior neurocognitive function preservation at 3 months and beyond with the SRS approach compared with the whole-brain RT. The standard for the 1 to 4 brain metastasis patient with the adequate KPS has shifted from the WBRT to the SRS. The SRS treats the individual lesions without the hippocampal memory impairment that WBRT causes.
- Frameless SRS uses the image guidance with the stereotactic localisation from the CBCT cone-beam CT acquired immediately before the treatment delivery. The image guidance replaces the rigid stereotactic head frame that required the neurosurgical frame placement under local anaesthesia. The frameless approach enables the hypofractionated 2 to 5-fraction SRS treatment of the larger lesions that single-fraction SRS would risk for the radionecrosis in the large-volume target.
- Trigeminal neuralgia SRS with the cobalt-60 multisource system delivers the 80 to 90 Gy to the trigeminal nerve root entry zone. The treatment provides the non-invasive radiosurgical option for the lancinating facial pain that the carbamazepine-refractory trigeminal neuralgia creates. The treatment achieves the 70 to 80 percent pain relief with minimal risk of the facial numbness. The microvascular decompression surgery achieves higher efficacy but greater procedural risk than the radiosurgical option.
- Radiosurgery for the spinal and paraspinal tumours and the oligometastatic spinal disease uses the robotic linac and the linac-based SBRT delivering 18 to 24 Gy in 1 to 3 fractions to the vertebral metastasis. The cord constraint limits the dose to the adjacent spinal cord. The ablative local control reaches the radioresistant histologies including the renal cell carcinoma and the melanoma metastasis that the conventional palliative EBRT cannot adequately control.
Similar technologies are also transforming adjacent markets. Learn more in our Proton Therapy Market.
4. Key Market Opportunity
Meaningful upside in the Stereotactic Radiosurgery market is centered on expanding multi-metastasis SRS capability, where treating ten or more brain metastases in a single session with multi-isocenter planning grows procedure volume from each eligible patient. Vendors with efficient multi-metastasis SRS planning and delivery capture this volume-expansion opportunity. Additional momentum comes from functional neurosurgery SRS expansion in essential tremor and other targets. As multi-metastasis SRS protocols grow and functional neurosurgery SRS expands, the addressable opportunity is growing from limited brain metastasis treatment toward comprehensive intracranial disease management.
5. Top Companies in the Stereotactic Radiosurgery Market
The following organisations hold leading positions in the Stereotactic Radiosurgery Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Varian Medical Systems
- Elekta
- Accuray
- Brainlab
- Hitachi
- RaySearch Laboratories
- ViewRay
6. Market Segmentation
The Stereotactic Radiosurgery Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By System | Gamma Knife CyberKnife LINAC-Based |
| By Indication | Brain Metastasis Acoustic Neuroma Trigeminal Neuralgia AVM Functional |
| By Fractionation | Single-Fraction Fractionated SRS |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Stereotactic Radiosurgery Market trajectory over the forecast period:
Brain Metastasis SRS Demonstrating Superior Neurocognitive Function Preservation at 3 Months Versus Whole-Brain RT Has Shifted the Standard for 1 to 4 Brain Metastasis From WBRT to Lesion-Specific SRS That Preserves Hippocampal Memory Function.The NCCTG N0574 and QUARTZ trials established that single-fraction SRS provides equivalent survival with superior neurocognitive preservation compared with whole-brain radiotherapy in patients with 1-3 brain metastases, fundamentally changing treatment philosophy for a condition affecting approximately 200,000 US patients annually. Varian TrueBeam and Accuray CyberKnife's SRS delivery systems achieve sub-millimetre accuracy through multiple non-coplanar beam arrangements or robotic arm positioning that concentrates radiation dose within the target while sparing surrounding brain. The extension to five or more brain metastases in trials from Yamamoto and the Radiosurgery Society has further expanded SRS eligibility beyond the three-metastasis threshold that originally defined the indication.
Frameless Image-Guided SRS Replacing Rigid Stereotactic Head Frame With CBCT Localisation Has Enabled Hypofractionated 2 to 5-Fraction Treatment of Larger Lesions Without the Frame Discomfort That Prevented Multi-Fraction SRS When Fixed-Frame Placement Was Required Each Session.SABR-COMET demonstrated improved 5-year overall survival of 42.3% versus 17.7% for patients receiving stereotactic ablative radiotherapy to all oligometastatic disease sites compared with palliative standard of care, establishing proof of concept for aggressive local therapy in limited metastatic burden cancer patients. The oligometastatic concept proposes that patients with 1-5 metastases have a biologically distinct disease state between curable localised cancer and incurable widespread metastases, making local ablation of all disease sites a potentially curative intent strategy. The NRG Oncology BR-002, CC-003, and multiple disease-specific SABR oligometastasis trials are generating the Phase 3 evidence base required to establish oligometastatic SABR as a standard of care that payers will reimburse as a standard rather than investigational treatment.
Spinal and Paraspinal SBRT 18 to 24 Gy in 1 to 3 Fractions With Cord Constraint Providing Ablative Local Control for Radioresistant Renal Cell Carcinoma and Melanoma Metastases Has Extended High-Dose Precision Radiotherapy to the Spinal Disease That Conventional EBRT Cannot Control.Proton SBRT in liver cancers achieves more conformal dose distributions than photon SBRT for tumours adjacent to radiosensitive structures including portal vein, bile ducts, and the stomach wall that constrain dose in photon-based stereotactic approaches. The CIRT Japan trial comparing carbon-ion therapy to proton SBRT in hepatocellular carcinoma is generating comparative effectiveness data across particle therapy modalities, with both achieving local control rates above 90% in early HCC. Proton SBRT's clinical niche in liver and pancreas is positioned between conventional photon SBRT in peripheral tumours and complex adaptive approaches in centrally located lesions, establishing a precision radiotherapy segmentation based on tumour location relative to critical adjacent structures.
For related market intelligence, see the Radiotherapy Market.
8. Segmental Analysis
By system, the linear-accelerator-based segment dominated the Stereotactic Radiosurgery Market in 2025, as Varian Medical Systems and Elekta platforms delivered the majority of intracranial and body radiosurgery procedures, generating the largest share of installed treatment capacity across radiation oncology centres.
By indication, the extracranial body segment is projected to register the highest growth rate through 2034, as stereotactic body radiotherapy expands across early-stage lung, liver, and prostate cancer where hypofractionated regimens offer an effective alternative to surgery for patients who are poor surgical candidates.
9. Regional Analysis
Regional demand patterns across the Stereotactic Radiosurgery Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Stereotactic Radiosurgery Market in 2025, accounting for approximately 43% of global revenue, attributed to the large installed base of Gamma Knife and CyberKnife units in the US and the clinical leadership in multi-metastasis SRS protocols. Moreover, LINAC-based SRS and functional neurosurgery applications are most advanced in US academic centres. In addition, brain metastasis SRS adoption is standard across US oncology. Regional dominance is due to this combination of infrastructure scale and clinical innovation.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Stereotactic Radiosurgery Market through 2034, driven by expanding Gamma Knife and LINAC-SRS installation across European countries and the large brain tumour and metastasis patient population. The region is also witnessing functional neurosurgery SRS growing with trigeminal neuralgia treatment. Moreover, multi-metastasis SRS adoption is advancing across European centres. The combination of these demand drivers and infrastructure expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Stereotactic Radiosurgery Market was valued at USD 2.87 Bn in 2025 and is projected to reach USD 5.84 Bn by 2034, growing at a CAGR of 8.2% over the 2026–2034 forecast period.
The Stereotactic Radiosurgery Market is projected to grow at a CAGR of 8.2% from 2026 to 2034.
North America dominated the Stereotactic Radiosurgery Market in 2025, accounting for approximately 43% of global revenue, attributed to the large installed base of Gamma Knife and CyberKnife units in the US and the clinical leadership in multi-metastasis SRS protocols.
The leading companies in the Stereotactic Radiosurgery Market include Varian Medical Systems, Elekta, Accuray, Brainlab, Hitachi, RaySearch Laboratories, ViewRay.
Brain metastasis srs demonstrating superior neurocognitive function preservation at 3 months versus whole-brain rt has shifted the standard for 1 to 4 brain metastasis from wbrt to lesion-specific srs that preserves hippocampal memory function.
By system, the linear-accelerator-based segment dominated the Stereotactic Radiosurgery Market in 2025, as Varian Medical Systems and Elekta platforms delivered the majority of intracranial and body radiosurgery procedures, generating the largest share of installed treatment capacity across radiation oncology centres.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.